Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers

Resignation of Alessandra Daigneault as Chief Corporate Officer, General Counsel and Corporate Secretary

On May 19, 2022, Ms. Alessandra Daigneault tendered her resignation as Chief Corporate Officer, General Counsel and Corporate Secretary of NRx Pharmaceuticals, Inc. (the "Company") effective on July 18, 2022 or such earlier date as may be agreed with the Company. Ms. Daigneault is leaving the Company to pursue other personal and professional interests.

The Company's interim Chief Executive Officer, Mr. Robert Besthof, expressed his thanks to Ms. Daigneault for her outstanding contributions to the Company, including overseeing the merger of NeuroRx, Inc, and Big Rock Partners Acquisition Corp in May 2021, which resulted in the formation of the Company.

Mr. Michael Kunz, the Company's Deputy General Counsel, is expected to assume the duties of General Counsel and Corporate Secretary.

Resignation of Mr. Ira Strassberg as Chief Financial Officer and Treasurer

On May 19, 2022, Mr. Ira Strassberg tendered his resignation as Chief Financial Officer and Treasurer of the Company effective July 18, 2022. Mr. Strassberg is leaving the Company to pursue other personal and professional interests. Mr. Strassberg will continue to fulfill his duties as Chief Financial Officer and Treasurer of the Company until his departure. The Board will be conducting a search for a successor.

The Chairman of the Company's Audit Committee, Mr. Patrick Flynn, and Mr. Besthof, expressed their thanks to Mr. Strassberg for his meaningful contributions to the Company, including the establishment of robust internal controls and a strong finance and accounting function at the Company.

2

© Edgar Online, source Glimpses